Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Seema Harichand-Herdt"'
Autor:
Richard C.K. Jordan, Jose P. Zevallos, Carole Fakhry, Bayardo Perez-Ordonez, John Thibo, Lisa M. Rooper, Erich M. Sturgis, Christina Lacchetti, Danny Rischin, Mark W. Lingen, Seema Harichand-Herdt, Diana Bell
Publikováno v:
Journal of Clinical Oncology. 36:3152-3161
Purpose The College of American Pathologists produced an evidence-based guideline on testing, application, interpretation, and reporting of human papillomavirus (HPV) and surrogate marker tests in head and neck carcinomas that was determined to be re
Autor:
Toncred M. Styblo, Yuan Liu, Monica Rizzo, Sheryl G. A. Gabram, Sungjin Kim, Amelia Zelnak, Seema Harichand-Herdt, William C. Wood, Ruth O'Regan
Publikováno v:
Clinical breast cancer. 13(3)
Neoadjuvant chemotherapy is widely used to downstage breast cancers before surgery. The addition of capecitabine to chemotherapy may improve the pathologic complete response rate (pCR), a robust predictor of outcome for certain breast cancer subtypes
Publikováno v:
Seminars in oncology. 36(6)
Lung cancer is the leading cause of cancer deaths in the United States. In recent years the incidence of lung cancer in men has been declining, while in women it has been increasing. A number of population-based studies have demonstrated gender-based
Publikováno v:
Expert review of anticancer therapy. 9(2)
The treatment of women with estrogen receptor-positive breast cancer has advanced significantly in the past decade. Tamoxifen was the gold standard hormonal therapy for breast cancer until the introduction of aromatase inhibitors and fulvestrant. Man
Publikováno v:
Seminars in thoracic and cardiovascular surgery. 20(3)
Systemic chemotherapy is the standard treatment for patients with advanced stage non-small cell lung cancer (NSCLC) and improves both their survival and quality of life. Despite this, the overall prognosis for advanced NSCLC remains poor. Molecularly
Autor:
R. C. Hermann, Jayanthi Srinivasiah, Harvey L. Bumpers, Monica Rizzo, F. M. Schnell, Seema Harichand-Herdt, Amelia Zelnak, Toncred M. Styblo, Ruth O'Regan, Sheryl G. A. Gabram
Publikováno v:
Journal of Clinical Oncology. 29:1118-1118
1118 Background: Achievement of pathologic complete response (pCR) to preoperative therapy is a predictor of improved disease-free and overall survival. Sequential and concurrent regimens of D and C were evaluated in patients with Her2-negative breas
Autor:
R. C. Hermann, Toncred M. Styblo, D Hicklin, K Carlson, Jayanthi Srinivasiah, Harvey L. Bumpers, N Sellers, Seema Harichand-Herdt, F. M. Schnell, Ruth O'Regan, Monica Rizzo, Amelia Zelnak, Carl J. D'Orsi, Sheryl G. A. Gabram, T Pierce, D Senior-Crosby
Publikováno v:
Cancer Research. 69:5122
Abstract #5122 Background The efficacy of D and C as single agents and in combination is well established in the treatment of metastatic breast cancer. Novel sequential and concurrent regimens of D and C were evaluated in patients with her2-negative
Autor:
Fakhry C; Carole Fakhry and Lisa M. Rooper, Johns Hopkins School of Medicine, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Richard C. Jordan, University of California, San Francisco, San Francisco, CA; Danny Rischin, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Erich M. Sturgis and Diana Bell, MD Anderson Cancer Center, Houston, TX; Mark W. Lingen, University of Chicago, Chicago, IL; Seema Harichand-Herdt, Mid Florida Cancer Center, Orange City, FL; John Thibo, Support for People with Oral and Head and Neck Cancer, Cleveland, OH; Jose Zevallos, Washington University School of Medicine, St. Louis, MO; and Bayardo Perez-Ordonez, University Health Network, Toronto, Ontario, Canada., Lacchetti C; Carole Fakhry and Lisa M. Rooper, Johns Hopkins School of Medicine, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Richard C. Jordan, University of California, San Francisco, San Francisco, CA; Danny Rischin, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Erich M. Sturgis and Diana Bell, MD Anderson Cancer Center, Houston, TX; Mark W. Lingen, University of Chicago, Chicago, IL; Seema Harichand-Herdt, Mid Florida Cancer Center, Orange City, FL; John Thibo, Support for People with Oral and Head and Neck Cancer, Cleveland, OH; Jose Zevallos, Washington University School of Medicine, St. Louis, MO; and Bayardo Perez-Ordonez, University Health Network, Toronto, Ontario, Canada., Rooper LM; Carole Fakhry and Lisa M. Rooper, Johns Hopkins School of Medicine, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Richard C. Jordan, University of California, San Francisco, San Francisco, CA; Danny Rischin, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Erich M. Sturgis and Diana Bell, MD Anderson Cancer Center, Houston, TX; Mark W. Lingen, University of Chicago, Chicago, IL; Seema Harichand-Herdt, Mid Florida Cancer Center, Orange City, FL; John Thibo, Support for People with Oral and Head and Neck Cancer, Cleveland, OH; Jose Zevallos, Washington University School of Medicine, St. Louis, MO; and Bayardo Perez-Ordonez, University Health Network, Toronto, Ontario, Canada., Jordan RC; Carole Fakhry and Lisa M. Rooper, Johns Hopkins School of Medicine, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Richard C. Jordan, University of California, San Francisco, San Francisco, CA; Danny Rischin, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Erich M. Sturgis and Diana Bell, MD Anderson Cancer Center, Houston, TX; Mark W. Lingen, University of Chicago, Chicago, IL; Seema Harichand-Herdt, Mid Florida Cancer Center, Orange City, FL; John Thibo, Support for People with Oral and Head and Neck Cancer, Cleveland, OH; Jose Zevallos, Washington University School of Medicine, St. Louis, MO; and Bayardo Perez-Ordonez, University Health Network, Toronto, Ontario, Canada., Rischin D; Carole Fakhry and Lisa M. Rooper, Johns Hopkins School of Medicine, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Richard C. Jordan, University of California, San Francisco, San Francisco, CA; Danny Rischin, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Erich M. Sturgis and Diana Bell, MD Anderson Cancer Center, Houston, TX; Mark W. Lingen, University of Chicago, Chicago, IL; Seema Harichand-Herdt, Mid Florida Cancer Center, Orange City, FL; John Thibo, Support for People with Oral and Head and Neck Cancer, Cleveland, OH; Jose Zevallos, Washington University School of Medicine, St. Louis, MO; and Bayardo Perez-Ordonez, University Health Network, Toronto, Ontario, Canada., Sturgis EM; Carole Fakhry and Lisa M. Rooper, Johns Hopkins School of Medicine, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Richard C. Jordan, University of California, San Francisco, San Francisco, CA; Danny Rischin, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Erich M. Sturgis and Diana Bell, MD Anderson Cancer Center, Houston, TX; Mark W. Lingen, University of Chicago, Chicago, IL; Seema Harichand-Herdt, Mid Florida Cancer Center, Orange City, FL; John Thibo, Support for People with Oral and Head and Neck Cancer, Cleveland, OH; Jose Zevallos, Washington University School of Medicine, St. Louis, MO; and Bayardo Perez-Ordonez, University Health Network, Toronto, Ontario, Canada., Bell D; Carole Fakhry and Lisa M. Rooper, Johns Hopkins School of Medicine, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Richard C. Jordan, University of California, San Francisco, San Francisco, CA; Danny Rischin, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Erich M. Sturgis and Diana Bell, MD Anderson Cancer Center, Houston, TX; Mark W. Lingen, University of Chicago, Chicago, IL; Seema Harichand-Herdt, Mid Florida Cancer Center, Orange City, FL; John Thibo, Support for People with Oral and Head and Neck Cancer, Cleveland, OH; Jose Zevallos, Washington University School of Medicine, St. Louis, MO; and Bayardo Perez-Ordonez, University Health Network, Toronto, Ontario, Canada., Lingen MW; Carole Fakhry and Lisa M. Rooper, Johns Hopkins School of Medicine, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Richard C. Jordan, University of California, San Francisco, San Francisco, CA; Danny Rischin, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Erich M. Sturgis and Diana Bell, MD Anderson Cancer Center, Houston, TX; Mark W. Lingen, University of Chicago, Chicago, IL; Seema Harichand-Herdt, Mid Florida Cancer Center, Orange City, FL; John Thibo, Support for People with Oral and Head and Neck Cancer, Cleveland, OH; Jose Zevallos, Washington University School of Medicine, St. Louis, MO; and Bayardo Perez-Ordonez, University Health Network, Toronto, Ontario, Canada., Harichand-Herdt S; Carole Fakhry and Lisa M. Rooper, Johns Hopkins School of Medicine, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Richard C. Jordan, University of California, San Francisco, San Francisco, CA; Danny Rischin, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Erich M. Sturgis and Diana Bell, MD Anderson Cancer Center, Houston, TX; Mark W. Lingen, University of Chicago, Chicago, IL; Seema Harichand-Herdt, Mid Florida Cancer Center, Orange City, FL; John Thibo, Support for People with Oral and Head and Neck Cancer, Cleveland, OH; Jose Zevallos, Washington University School of Medicine, St. Louis, MO; and Bayardo Perez-Ordonez, University Health Network, Toronto, Ontario, Canada., Thibo J; Carole Fakhry and Lisa M. Rooper, Johns Hopkins School of Medicine, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Richard C. Jordan, University of California, San Francisco, San Francisco, CA; Danny Rischin, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Erich M. Sturgis and Diana Bell, MD Anderson Cancer Center, Houston, TX; Mark W. Lingen, University of Chicago, Chicago, IL; Seema Harichand-Herdt, Mid Florida Cancer Center, Orange City, FL; John Thibo, Support for People with Oral and Head and Neck Cancer, Cleveland, OH; Jose Zevallos, Washington University School of Medicine, St. Louis, MO; and Bayardo Perez-Ordonez, University Health Network, Toronto, Ontario, Canada., Zevallos J; Carole Fakhry and Lisa M. Rooper, Johns Hopkins School of Medicine, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Richard C. Jordan, University of California, San Francisco, San Francisco, CA; Danny Rischin, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Erich M. Sturgis and Diana Bell, MD Anderson Cancer Center, Houston, TX; Mark W. Lingen, University of Chicago, Chicago, IL; Seema Harichand-Herdt, Mid Florida Cancer Center, Orange City, FL; John Thibo, Support for People with Oral and Head and Neck Cancer, Cleveland, OH; Jose Zevallos, Washington University School of Medicine, St. Louis, MO; and Bayardo Perez-Ordonez, University Health Network, Toronto, Ontario, Canada., Perez-Ordonez B; Carole Fakhry and Lisa M. Rooper, Johns Hopkins School of Medicine, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Richard C. Jordan, University of California, San Francisco, San Francisco, CA; Danny Rischin, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Erich M. Sturgis and Diana Bell, MD Anderson Cancer Center, Houston, TX; Mark W. Lingen, University of Chicago, Chicago, IL; Seema Harichand-Herdt, Mid Florida Cancer Center, Orange City, FL; John Thibo, Support for People with Oral and Head and Neck Cancer, Cleveland, OH; Jose Zevallos, Washington University School of Medicine, St. Louis, MO; and Bayardo Perez-Ordonez, University Health Network, Toronto, Ontario, Canada.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2018 Nov 01; Vol. 36 (31), pp. 3152-3161. Date of Electronic Publication: 2018 Sep 06.